Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of Alabama at Birmingham
Birmingham, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of Alabama at Birmingham (34)
2024
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235
-
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Advances in Therapy
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide
The Lancet Oncology, Vol. 24, Núm. 12, pp. e472-e518
-
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014
-
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840
2022
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293
-
Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
The American journal of gastroenterology, Vol. 117, Núm. 5, pp. 818
-
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
Critical Care, Vol. 26, Núm. 1
-
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284
-
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
American Journal of Gastroenterology, Vol. 117, Núm. 2, pp. 301-310
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease
New England Journal of Medicine, Vol. 387, Núm. 5, pp. 421-432
-
Variations in management of A3 and A4 cervical spine fractures as designated by the AO Spine Subaxial Injury Classification System
Journal of Neurosurgery: Spine, Vol. 36, Núm. 1, pp. 99-112
2021
-
Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118